Amgen Report Results of Sotorasib in P-II CodeBreaK 100 Study for Advanced Non-Small Cell Lung Cancer
Shots:
- The P-ll CodeBreaK 100 study involves assessing of Sotorasib (proposed INN for AMG 510- 960mg) in 126 patients with KRAS G12C-mutant advanced NSCLC- whose cancer had progressed despite prior treatment with CT and/or immunotherapy
- Result: ORR is consistent with previously reported P-I study while other measures of efficacy including DoR are promising and 50%+ of the responders were still on treatment and continuing to respond as of the data cutoff date whereas safety & tolerability is similar to previous P-I data
- Detailed results of the P-II study will be submitted to the IASLC 2020 World Congress on Lung Cancer while the company has begun recruiting in P-III CodeBreaK 200 study evaluating Sotorasib vs docetaxel in KRAS G12C-mutant NSCLC patients
Ref: Amgen | Image: Reuters
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com